Tactile Systems Technology, Inc. (TCMD) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Weak operating margin ⢠Strong cash generation TCMD delivers very high gross margins, strong liquidity and free cash flow with low leverage, but elevated SG&A compresses operating margins and the stock appears richly valued.
Price Behavior
Key Price Behavior Insights: ⢠Strong downtrend ⢠Below SMA ⢠Midâ$25 support Support Level: $25.00â$26.50 Resistance Level: $28.00â$30.00 Over the last month the stock has dropped ~16% to $24.60 and is trading well below its ~$27.08 moving average, indicating short-term bearish momentum with nearby support near $25.0â$26.5 and resistance around $28â$30.
Sentiment & News
Key News Insights: ⢠Analyst optimism ⢠Board appointment ⢠GenAI adoption Tactile Systems saw rising analyst optimism and a new board appointment alongside positioning for GenAI-driven product gains, though sector headwinds could temper upside.
AI Summary
TCMD has shifted into a cashâgenerative, deâlevered growth profile where upside now depends on converting its very high gross margins into durable operatingâprofit through AffloVest commercialization, salesforce scale and AI/CRM-driven order automation. Key risk: monitor quarterly EBITDA margin expansion, AffloVest adoption rates, and LCDâNCD reimbursement milestonesâfailure to show sustained operating leverage or timely payer wins will rapidly negate current valuation support.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |